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Abstract
In medical practice, when more than one treatment option is viable, there is little
systematic use of individual patient characteristics to estimate which treatment option
is most likely to result in a better outcome for the patient. This is due in part because
practitioners do not have any easy way to holistically evaluate whether their treatment
allocation procedure does better than the standard of care — a metric we term “improve-
ment.” Herein, we present easy-to-use open-source software that provides inference for
improvement in many scenarios, the R package PTE, “Personalized Treatment Evaluator”
and in the process introduce methodological advances in personalized medicine. In the
software, the practitioner inputs (1) data from a single-stage randomized trial with one
continuous, incidence or survival endpoint and (2) a functional form of a model for the
endpoint constructed from domain knowledge. The bootstrap is then employed on out-of-
sample data to provide confidence intervals for the improvement for future patients. One
may also test against a null scenario where the hypothesized model’s treatment allocations
are not more useful than the standard of care. We demonstrate our method’s promise on
simulated data as well as on data from a randomized trial investigating two treatments
for depression.
Keywords: personalized medicine, inference, bootstrap, treatment regime, randomized com-
parative trial, statistical software.
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2 Inference for the Effectiveness of Personalized Medicine with Software
1. Introduction
Medical patients often respond differently to treatments and can experience varying side ef-
fects. Personalized medicine, sometimes called “precision medicine” or “stratified medicine”
(Smith 2012), is a medical paradigm offering the possibility for improving the health of in-
dividuals by judiciously treating individuals based on his or her heterogeneous prognostic or
genomic information (Zhao and Zeng 2013). The interest in such personalization is exploding.
Fundamentally, personalized medicine is a statistical problem and much recent statistical
research has focused on how to best estimate dynamic treatment regimes or adaptive inter-
ventions (Collins et al. 2004; Chakraborty and Murphy 2014). These are essentially strategies
that vary treatments administered over time as more is learned about how particular patients
respond to one or more interventions. Elaborate models are often proposed that purport to
estimate optimal dynamic treatment regimes from multi-stage experiments (Murphy 2005b)
as well as the more difficult situation of inference in observational studies.
The extant work, at least in the field of statistics, is highly theoretical. There is a dearth of
software that can answer two fundamental questions practitioners will need answered before
they can personalize future patients’ treatments:
• How much better is this personalization model expected to perform when compared to
my previous “naive” strategy for allocating treatments?
• How confident can I be in this estimate? Can I reject a null hypothesis that it will
perform no better than the standard of care?
Chakraborty and Moodie (2013, page 168) believe that “more targeted research is warranted”
on these questions of import; and the goal of our paper is to provide a framework and usable
software that fills in this gap.
Personalized medicine is a broad paradigm encompassing many real-world situations. One
common situation is using previous randomized comparative / controlled trial (RCT) data to
be able to make better decisions for future patients. We consider RCT’s with two treatment
options (two-arm), with one endpoint measure (also called the “outcome” or “response” which
can be continuous, binary or survival) and where the researchers also collected a variety of
patient characteristics to be used for personalization. The practitioner also has an idea of
a model of the response (usually a simple first-order interaction model). Our software then
answers the two critical questions listed above.
The paper proceeds as follows. In Section 2, we review the modern personalized medicine
literature and locate our method within. Section 3 describes our methods and its limitations
in depth, by describing the conceptual framework emphasizing our methodological advances.
We then carefully specify the data and model inputs, define the improvement metric, and
illustrate a strategy for providing practitioners with estimates and inference. Section 4 applies
our methods to (1) a simple simulated dataset in which the response model is known, (2) a
more complicated dataset characterized by an unknown response model and (3) a real data
set from a published clinical trial investigating two treatments for a major depressive disorder.
Section 5 demonstrates the software for all three types of endpoints: continuous, binary and
survival. Section 6 concludes and offers future directions of which there are many.
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2. Background
Consider an individual seeking one of two treatments, neither of which is known to be superior
for all individuals. “What treatment, by whom, is most effective for this individual with that
specific problem, and under which set of circumstances?” (Paul 1967).1 Sometimes practition-
ers will select a treatment based informally on personal experience. Other times, practitioners
may choose the treatment that their clinic or peers recommend. If the practitioner happens to
be current on the research literature and there happens to be a published RCT whose results
have clear clinical implications, the study’s “superior” treatment on average may be chosen.
Each of these approaches can sometimes lead to improved outcomes, but each also can be badly
flawed. For example, in a variety of clinical settings, “craft lore” has been demonstrated to
perform poorly, especially when compared to very simple statistical models (Dawes 1979). It
follows that each of these “business-as-usual” treatment allocation procedures can in principle
be improved if there are patient characteristics available which are related to how well an
intervention performs. Patient“characteristics”and“circumstances”, also known as“features,”
“states,” “histories,” “prognostic / prescriptive factors,” “pretreatment variables,” and other
terms of art, we will consider here to be “covariates”, as they will be used in a regression
modeling context.
The need for personalized medicine via the use of such covariates is by no means a novel idea.
As noted as early as 1865, “the response of the average patient to therapy is not necessarily
the response of the patient being treated” (see the Bernard 1957 translation). There is now
a substantial literature addressing numerous aspects of personalized medicine and the field is
quite fragmented. Generally speaking, there is literature on treatment-covariate interactions,
locating subgroups of patients and personalized treatment effects estimation. A focus on
inference is rare in the literature and available software for inference is negligible.
Byar (1985) provides an early review of work involving treatment-covariate interactions. Byar
and Corle (1977) investigates tests for treatment-covariate interactions in survival models
and discusses methods for treatment recommendations based on covariate patterns. Shuster
and van Eys (1983) considers two treatments and proposes a linear model composed of a
treatment effect, a prognostic factor, and their interaction. Using this model, the authors
create confidence intervals to determine for which values of the prognostic factor one of two
treatments is superior.
Many researchers also became interested in discovering “qualitative interactions”, which are
interactions that create a subset of patients for which one treatment is superior and another
subset for which the alternative treatment is superior. Gail and Simon (1985) develop a
likelihood ratio test for qualitative interactions which was further extended by Pan and Wolfe
(1997) and Silvapulle (2001). For information and another approach, see Foster (2013).
Much of the early work in detecting these interactions required a prior specification of sub-
groups. This can present significant difficulties in the presence of high dimensionality or com-
plicated associations. More recent approaches such as Su et al. (2009) and Dusseldorp and
Van Mechelen (2014) favor recursive partitioning trees that discover important nonlinearities
1Note that this problem is encountered in fields outside of just medicine. For example, finding the movie that
will elicit the most enjoyment to the individual Zhou et al. (2008) or assessing wither a certain unepmployed
individual be given job training (see the work of LaLonde 1986). Although the methods discussed herein can
be applied more generally, we will use examples and the specific vocabulary within medicine for convenience
and intuition.
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and interactions. Dusseldorp et al. (2016) introduce software (an R package called QUINT)
that outputs binary trees breaking participants into subgroups. Shen and Cai (2016) propose
a kernal machine score test to identify interactions and the test has more power than the
classic Wald test when the predictor effects are non-linear and when there is a large number
of predictors. Berger et al. (2014) discuss a method for creating prior subgroup probabilities
and provides a Bayesian method for uncovering interactions and identifying subgroups.
In our method, we make use of RCT data. Thus, it is important to remember that “clinical
trials are typically not powered to examine subgroup effects or interaction effects, which
are closely related to personalization... even if an optimal personalized medicine rule can
provide substantial gains it may be difficult to estimate this rule with few subjects” (Rubin
and van der Laan 2012). This is why a major bulk of the literature focuses on not finding
covariate-treatment interactions or locating subgroups of individuals, but the entire model
itself (sometimes called “regimes”) that is then used to sort individuals. Holistic statements
can then be made on the basis of this entire sorting procedure. We turn to selected literature
now.
Zhang et al. (2012a) consider the context of treatment regime estimation in the presence of
model misspecification when there is a single-point treatment decision. By applying a doubly-
robust augmented inverse probability weighted estimator that under the right circumstances
can adjust for confounding and by considering a restricted set of policies, their approach can
help protect against misspecification of either the propensity score model or the regression
model for patient outcome. Brinkley et al. (2010) develop a regression-based framework of a
dichotomous response for personalized treatment regimes within the rubric of “attributable
risk”. They propose developing optimal treatment regimes that minimize the probability of
a poor outcome, and then consider the positive consequences, or “attributable benefit”, of
their regime. They also develop asymptotically valid inference for a parameter similar to
improvement with business-as-usual as the random, an idea we extend. Within the literature,
their work is the closest conceptually to ours. Gunter et al. (2011b) develop a stepwise
approach to variable selection and Gunter et al. (2011a) compares it to stepwise regression.
Rather than using a traditional sum-of-squares metric, the authors’ method compares the
estimated mean response, or“value,”of the optimal policy for the models considered, a concept
we make use of in Section 3. Imai and Ratkovic (2013) use a modified Support Vector Machine
with LASSO constraints to select the variables useful in an optimal regime when the response
is binary. van der Laan (2013) use a loss-based super-learning approach with cross-validation.
Also important within the area of treatment regime estimation, but not explored in this paper,
is the estimation of dynamic treatment regimes (DTRs). DTRs constitute a set of decision
rules, estimated from many experimental and longitudinal intervals. Each regime is intended
to produce the highest mean response over that time interval. Naturally, the focus is on
optimal DTRs — the decision rules which provide the highest mean response. Murphy (2003)
and Robins (2004) develop two influential approaches based on regret functions and nested
mean models respectively. Moodie et al. (2007) discusses the relationship between the two
while Moodie and Richardson (2009) and Chakraborty et al. (2010) present approaches for
mitigating biases (Chakraborty et al. 2010 also fixes biases in model parameter estimation
stemming from their non-regularity in SMART trials). Robins et al. (2008) focus on using
observational data and optimizing the time for administering the stages — the“when to start”
— within the DTR. Orellana et al. (2010) develop a different approach for estimating optimal
DTRs based on marginal structural mean models. Henderson et al. (2010) develop optimal
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DTR estimation using regret functions and also focus on diagnostics and model checking.
Barrett et al. (2013) develop a doubly robust extension of this approach for use in observational
data. Laber et al. (2014) demonstrate the application of set-valued DTRs that allow balancing
of multiple possible outcomes, such as relieving symptoms or minimizing patient side effects.
Their approach produces a subset of recommended treatments rather than a single treatment.
Also, McKeague and Qian (2014) estimate treatment regimes from functional predictors in
RCTs to incorporate biosignatures such as brain scans or mass spectrometry.
Many of the procedures developed for estimating DTRs have roots in reinforcement learning.
Two widely-used methods are Q-learning (Murphy 2005a) and A-learning (see Schulte and
Tsiatis 2012 for an overview of these concepts). One well-noted difficulty with Q-learning
and A-learning are their susceptibility to model misspecification. Consequently, researchers
have begun to focus on “robust” methods for DTR estimation. Zhang et al. (2013) extends
the doubly-robust augmented inverse probability weighted method in Zhang et al. (2012a)
method by considering multiple binary treatment stages.
Many of the methods mentioned above can be extended to censored survival data. Zhao
et al. (2015) describes a computationally efficient method for estimating a treatment regimes
that maximizes mean survival time by extending the weighted learning inverse probability
method. This method is doubly robust; it is protected from model misspecification if either the
censoring model or the survival model is correct. Additionally, methods for DTR estimation
can be extended. Goldberg and Kosorok (2012) extends Q-learning with inverse-probability-
of-censoring weighting to find the optimal treatment plan for individual patients, and the
method allows for flexibility in the number of treatment stages. The Matlab code for this
method is available online. In addition, methods can be extended for estimating heterogeneity
in treatment effects.
It has been tempting, when creating these treatment regime models, to directly employ then
to predict the differential response of individuals among different treatments. This is called
in the literature “heterogeneous treatment effects models” or “individualized treatment rules”
and there is quite a lot of interest in it.
Surprisingly, methods designed for accurate estimation of an overall conditional mean of the
response may not perform well when the goal is to estimate these individualized treatment
rules. Qian and Murphy (2011), propose a two-step approach to estimating “individualized
treatment rules”based on single-stage randomized trials using `1-penalized regression while Lu
et al. (2011) and Lu et al. (2013) use quadratic loss which facilitates variable selection. Rolling
and Yang (2014) develop a new form of cross-validation which chooses between different
heterogeneous treatment models.
One current area of research in heterogeneous effect estimation is the development of algo-
rithms that can be used to create finer and more accurate partitions. Kallus (2017) presents
three methods for the case of observational data: greedily partitioning data to find optimal
trees, bootstrap aggregating to create a “personalization forest” a la Random Forests, and
using the tree method coupled with mixed integer programming to find the optimal tree. La-
mont et al. (2016) builds on the prior methods, parametric multiple imputation and recursive
partitioning, to estimate heterogeneous treatment effects and compares the performance of
both methods. This estimation can be extended to censored data. Henderson et al. (2017)
discuss the implementation of Bayesian additive regression trees for estimating heterogeneous
effects, and they can be used for continuous, binary and censored data. An R package imple-
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menting their methods is forthcoming.
One major drawback of many of the approaches in the literature reviewed is their significant
difficulty evaluating estimator performance. Put another way, given the complexity of the
estimation procedures, statistical inference is very challenging. Many of the approaches re-
quire that the proposed model be correct. There are numerous applications in the biomedical
sciences for which this assumption is neither credible on its face nor testable in practice. For
example, Evans and Relling (2004) consider pharmacogenomics, and argue that as our un-
derstanding of the genetic influences on individual variation in drug response and side-effects
improves, there will be increased opportunity to incorporate genetic moderators to enhance
personalized treatment. But we will ever truly understand such a complicated model? Fur-
ther, other biomarkers (e.g. neuroimaging) of treatment response have begun to emerge, and
the integration of these diverse moderators will require flexible approaches that are robust
to model misspecification (McGrath et al. 2013). How will the models of today incorporate
important relationships that can be anticipated but have yet to be identified? Further, many
proposed methods employ non-parametric models use the data to decide which internal pa-
rameters to fit and then in turn estimates these internal parameters. Thus a form of model
selection that introduces difficult inferential complications (see Berk et al. 2013b).
At the very least, therefore, there should be an alternative inferential framework for evaluating
treatment regimes that do not require correct model specification (and thereby obviating the
need for model checking and diagnostics) nor unmeasured confounders (see discussion in
Henderson et al. 2010) accompanied by easy-to-use software. This is the modest goal herein.
3. Methodology
3.1. Conceptual Framework
We imagine a set of random variables having a joint probability distribution that can be
properly seen as a population from which data could be randomly and independently realized.
The population can also be imagined as all potential observations that could be realized from
the joint probability distribution. Either conception is consistent with our setup.
A researcher chooses one of the random variables to be the response Y which could be con-
tinuous, binary or survival (with a corresponding censoring variable, explained later). We
assume without loss of generality that a greater-valued outcome is better for all individuals.
Then, one or more of the other random variables are covariates X ∈ X . At the moment, we
do not distinguish between observed and unobserved covariates but we will later. There is
then a conditional distribution P (Y | X) whose conditional expectation E [Y | X] constitutes
the overall population response surface. No functional forms are imposed and for generality
we allow the functional form to be nonlinear with interactions among the covariates.
All potential observations are hypothetical study subjects. Each can be exposed to a treatment
denoted A ∈ A. In our formulation, we assume one experimental condition T1 (which may
be considered the “control” or “comparison” condition) and another experimental condition
T2 coded as 0 and 1 respectively. Thus, A = {0, 1}. We make the standard assumption of
no interference between study subjects, which means that the outcome for any given subject
is unaffected by the interventions to which other subjects are randomly assigned (Cox 1958).
Outcomes under either condition can vary over subjects (Rosenbaum 2002, Section 2.5.1). In
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short, we employ the conventional Neyman-Rubin approach (Rubin 1974) but treat all the
data as randomly realized (Berk et al. 2013a).
A standard estimation target in RCTs is the population average treatment effect (PATE), de-
fined here as E [Y | A = 1]−E [Y | A = 0], the difference between the population expectations
. That is, the PATE is defined as the difference in mean outcome were all subjects exposed
to T2 or alternatively were all exposed to T1. In a randomized controlled trial, the PATE is
synonymous with the overall efficacy of the treatment of interest and it is almost invariably
the goal of the trial (Zhao and Zeng 2013).
For personalization, we want to make use of any association between Y and X. For the hy-
pothetical study subjects, there is a conditional population response surface E [Y | X, A = 1]
and another conditional population response surface E [Y | X, A = 0], a key objective being
to exploit the difference in these response surfaces for better treatment allocation. The typical
approach is to create a deterministic individualized treatment decision rule d ∈ D that takes
an individual’s covariates and maps them to a treatment. We seek d : X → A based on
knowledge of the differing conditional population response surfaces. The rule is sometimes
called an allocation procedure because it determines which treatment to allocate based on
measurements made on the individual. To compare different allocation procedures, our met-
ric is the expectation of the outcome Y using the allocation procedure d averaged over all
subjects X . Following the notation of Qian and Murphy (2011), we denote this expectation
as the value of the decision rule
V [d] , EdX,A [Y ] ,
∫
X
(∑
a∈A
(∫
R
yfY |X,A(y,x, a)dy
)
1a=d(x)
)
fX(x)dx. (1)
Although the integral expression appears complicated, when unpacked it is merely an ex-
pectation of the response averaged over X , the space of all patients, on the set of current
measurements of patient characteristics. When averaging over X , different treatments will be
recommended based on the rule, i.e. a = d(x), and that in turn will modify the density of
the response, fY |X . Put another way, V [d] is the mean patient outcome when personalizing
each patient’s treatment.
We have considered all covariates to be random variables because we envision future patients
for whom an appropriate treatment is required. Ideally, their covariate values are realized
from the same joint distribution as the covariate values for the study subjects. In effect, our
enterprise requires forecasts for each patient.
In addition, we do not intend to rely on estimates of the two population response surfaces. As
a practical matter, we will make do with a population response surface approximation for each.
No assumptions are made about the nature of these approximations and in particular, how
well or poorly either population approximation corresponds to the true conditional response
surfaces.
Recall that much of the recent literature has been focused on finding the optimal rule,
d∗ , arg max d∈D {V [d]}. Although this is an admirable ideal (see Qian and Murphy 2011),
our goals here are more modest. We envision an imperfect rule d, and we wish to gauge its
performance relative to the performance of another rule d0, where the “naught” denotes a
business-as-usual allocation procedure, sometimes called “standard of care” or “current prac-
tice”. Thus, we define the population value improvement µI0 as the value of d minus the value
of d0,
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µI0 , V [d]− V [d0] = EdX,A [Y ]− Ed0X,A [Y ] . (2)
Since our convention is that higher response values are better, we seek large, positive improve-
ments that translate to better average performance (as measured by the response). Note that
this is a natural measure when Y is continuous. When Y is incidence or survival, improvement
may need to be redefined (we explore this later in Sections 3.4.2 and 3.4.3).
Usually improvement is not stated explicitly as the target of estimation and inference, and
thus our framework differs slightly from what is found in the literature. However, importance
is the essential comparison one makes in practice (Kallus 2017) and we believe this is the first
time it is made explicit.
3.2. Our framework’s required inputs
Our method depends on two inputs (1) access to RCT data and (2) either a prespecified
parametric model f(x, A,θ) for the population approximation of the true response surfaces or
an explicit d function. If we prespecified f , we then use the RCT data to estimate parameters
of the model θ, and the estimates are embedded in the model structure and denoted fˆ . This
model estimate permits us, in turn, to construct an estimated decision rule dˆ and an estimate
of the improved outcomes future subjects will experience (explained later in Section 3.4). We
assume that the model f is specified before looking at the data. To allow “data snooping”
(running our method, checking the p-value, changing the model and running again) fosters
overfitting, can introduce serious estimation bias, and can invalidate confidence intervals and
statistical tests we develop further on (Berk et al. 2013b). Fitting the model from the data
automatically and simultaneously providing inference we view as much needed future work.
The RCT data
The RCT data come from an experiment undertaken to estimate the PATE for treatments T1
and T2 for a diagnosis of a disease of interest. T1 and T2 are the same treatments one would
offer to future subjects with the same diagnosis. There are n subjects each with p covariates
which are denoted for the ith subject as xi , [xi1, xi2, . . . , xip] that can be continuous or
binary. Because the covariates will be used to construct a decision rule applied with future
patients in clinical settings, the xi’s in the RCT data must be the same covariates measured in
the same way for new subjects in the future. Thus, all “purely experimental covariates” such
as site of treatment (in a multi-center trial) or the identification of the medical practitioner
who treated each subject or either hindsight-only variables are not included.
We assume the outcome measure of interest yi is assessed once per subject. Aggregating all
covariate vectors, binary allocations and responses row-wise, we denote the full RCT data as
the column-bound matrix [X,A,y]. In practice, missing data can be imputed (in both the
RCT data and the future data), but herein we assume complete data.
We will be drawing inference to a patient population beyond those who participated in the
experiment. Formally, new subjects in the future must be sampled from that same population
as were the subjects in the RCT. In the absence of explicit probability sampling, the case
would need to be made (from subject-matter expertise and the manner in which the study
subjects were recruited) that the model can generalize.
Adam Kapelner, Justin Bleich, Alina Levine, Zachary D. Cohen, Robert J. DeRubeis, Richard Berk9
The Model f
If the practitioner has decided upon an approximate response model f a priori, a function
of x and A, Our decision rule d is a function of x through f — allocations are assigned by
comparing an individual’s f(x) for both T1 and T2 and assigning the higher response estimate.
Thus, we define d, our decision rule of interest as
d[f(x)] , arg max
A∈A
f(x, A) = 1f(x,1)−f(x,0). (3)
As in Berk et al. (2014), we assume the model f provided by the practitioner to be an
approximation using the available covariates of the response’s true data generating process
thus the true expectation is
Yi = f(Xi, Ai) + ξi(Xi,U i, Ai)︸ ︷︷ ︸
E[Yi | Xi,U i,Ai]
+Ei. (4)
In Equation 4, X denotes the random covariates available in the RCT data and U represents
unobserved random covariates. The first two terms together compose the conditional expec-
tation of the population response. The last term Ei is the irreducible noise around the true
conditional expectations and is taken to be independent and identically distributed, mean-
centered and uncorrelated with the covariates. We emphasize that the proposed model f is
not the true conditional expectation function. Even in the absence of Ei, f will always dif-
fer from the true conditional expectation function by ξi(Xi,U i, Ai), which represents model
misspecification (see Box and Draper 1987, Chapter 13).
We wish only to determine whether fˆ is useful for improving treatment allocation for future
patients and do not expect to recover the optimal allocation rule d∗ (which requires access
to the U). Further, we do not concern ourselves with substantive interpretations associated
with any of the p covariates. Our method is robust to model misspecification by definition.
One implication is that a wide variety of models and estimation procedures for f could in
principle prove useful.
What could f look like in practice? Assume a continuous response (binary and survival
are discussed later) and consider the conventional linear regression model with first order
interactions. Much of the literature we reviewed in Section 2 favored this class of models.
We specify a linear model containing a subset of the covariates used as main effects and a
possibly differing subset of the covariates to be employed as first order interactions with the
treatment indicator,
{
x1′ , . . . , xp′
} ⊂ {x1, . . . , xp}, selected using domain knowledge:
f(xi1, Ai) = β0 + β1x1 + . . .+ βpxp +Ai
(
γ0 + γ1′x1′ + . . .+ γp′xp′
)
. (5)
These interactions induce heterogeneous effects between T1 and T2 for a subject x and thus
d[f(x)] = 1 when γ0 + γ1′x1′ + . . . + γp′xp′ > 0 and 0 otherwise. The γ’s are the critical
component of the model if there are systematic patient-specific responses to the interventions.
Thereby, d varies over different points in X space. Note that rules derived from this type of
conventional model also have the added bonus as being interpretable to the practitioner at
least as a best linear approximation.
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Again we stress that our models are not required to be of this form, but we introduce them
here mostly for familiarity and pedagogical simplicity. There are times when these models
will perform terribly even if
{
x1′ , . . . , xp′
}
are the correct moderating variables (for a non-
linear example, see Zhao and Zeng 2013 Figure 1, right). Although this model is the default
implementation, the user can specify any model desired in the software. This will be discussed
in Section 5.
3.3. Other allocation procedures
Although d0 can be any allocation rule, for the purposes of the paper, we examine only two
“business-as-usual” allocation procedures presented in Table 1.
Name Procedure Description
random random allocation to T1 or T2 with
probability 12
best unconditional allocation to the
“best” treatment on average as
measured by whichever sample group
average is numerically larger (i.e. y¯T1 or y¯T2)
Table 1: Two baseline business-as-usual allocation procedures denoted as d0. The best
procedure is considered conservative (Brinkley et al. 2010, Section 7).
A practitioner may not actually employ d0 precisely as specified by the descriptions of ran-
dom or best, but we view this as a good start for providing a baseline for comparison. The
table could be expanded to include other allocation procedures such as heuristics, simple
models and others. We consider other d0 choices in Section 6.
3.4. Estimating the improvement scores
For a Continuous Response
How well do future subjects with treatments allocated by d do on average compared to the
same future subjects with treatments allocated by d0? We start by computing the estimated
improvement score, a sample statistic given by
Iˆ0 , Vˆ [dˆ]− Vˆ [dˆ0], (6)
where dˆ is an estimate of the rule d derived from the population response surface approxi-
mation, Vˆ is an estimate of its corresponding value V and Iˆ0 is an estimate of the resulting
population improvement µI0 (Equation 2). The dˆ0 notation indicates that sometimes the
competitor d0 may have to be estimated from the data as well. For example, the allocation
procedure best (Table 1) must be calculated by using the sample average of the responses
for both T1 and T2 in the data.
In order to properly estimate future µI0 , we split the RCT data into two disjoint subsets:
training data with ntrain of the original n observations [Xtrain,ytrain] and testing data with
the remaining ntest = n − ntrain observations [Xtest,ytest]. Then fˆtrain can be fit using the
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training data to construct dˆ via Equation 3. Performance of dˆ as calculated by Equation 6,
is then evaluated on the test data. Hastie et al. (2013) explain that a single train-test split
yields an estimate of the “performance” of the procedure on future individuals conditional
on [Xtrain,ytrain], the “past”. By splitting the RCT data into training and test subsets, the
Iˆ0 statistic defined in Equation 6 can provide an honest assessment of improvement (i.e.
immune to overfitting in fˆ) who are allocated using our proposed methodology compared to
a baseline business-as-usual allocation strategy (Faraway 2013). This can be thought of as
employing a replicated trial, often required in drug development programs, which separates
rule construction (in-sample) from rule validation (out-of-sample) as recommended by Rubin
and van der Laan (2012). Note that this comes at a cost of more sample variability (as now
our estimate will be based on the test subset with a sample size much smaller than n). To
our knowledge, our framework and software is the first to provide out-of-sample validation as
a native feature.
Given the estimate dˆ and dˆ0, the question remains of how to explicitly compute Vˆ for subjects
we have not yet seen in order to estimate Iˆ0. That is, we are trying to estimate the expectation
of an allocation procedure over covariate space X .
Recall that in the test data, our allocation prediction dˆ(xi) is the binary recommendation
of T1 or T2 for each xtest,i. If we recommended the treatment that the subject actually was
allocated in the RCT, i.e. dˆ(xi) = Ai, we consider that subject to be “lucky.” We define lucky
in the sense that by the flip of the coin, the subject was randomly allocated to the treatment
that our model-based allocation procedure estimates to be the better of the two treatments.
The average of the lucky subjects’ responses should estimate the average of the response of
new subjects who are allocated to their treatments based on our procedure d. This average is
exactly the estimate of Vˆ (dˆ) we are seeking. Because the x’s in the test data are assumed to be
sampled randomly from population covariates, this sample average estimates the expectation
over X , i.e. EdX,A [Y ] conditional on the training set.
In order to make this concept more clear, it is convenient to consider Table 2, a 2× 2 matrix
which houses the sorted entries of the out-of-sample ytest based on the predictions, the dˆ(xi)’s.
The diagonal entries of sets P and S contain the “lucky subjects.” The off-diagonal entries
of sets R and Q contain other subjects. The notation y¯· indicates the sample average among
the elements of ytest specified in the subscript located in the cells of the table.
dˆ(xi) = 0 dˆ(xi) = 1
Ai = 0 P , {ytest,0,01 , . . . , ytest,0,0ntest0,0} Q , {ytest,0,11 , . . . , ytest,0,1ntest0,1}
Ai = 1 R , {ytest,1,01 , . . . , ytest,1,0ntest1,0} S , {ytest,1,11 , . . . , ytest,1,1ntest1,1}
Table 2: The elements of ytest cross-tabulated by their administered treatment Ai and our
model’s estimate of the better treatment dˆ(xi).
How do we compute Vˆ [dˆ0], the business-as-usual procedure. For rand, we simply average all
of the ytest responses; for best, we average the ytest responses for the treatment group that
has a larger sample average. Thus, the sample statistics of Equation 6 can be written as
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Iˆrandom , y¯P∪S − y¯test, (7)
Iˆbest , y¯P∪S −
{
y¯P∪Q when y¯P∪Q ≥ y¯R∪S
y¯R∪S when y¯P∪Q < y¯R∪S .
(8)
Note that the plug-in estimate of value y¯P∪S is traditional in the personalized medicine liter-
ature and is usually written as Chakraborty and Murphy (2014, Equation 3),
Vˆ (dˆ) :=
1
n
n∑
i=1
Yi1dˆ(xi)=Ai . (9)
There is one more conceptual point. Recall that the value estimates Vˆ [·] are conditional on
the training set. This means they do not estimate the unconditional EdX,A [Y ]. To address
this, Hastie et al. (2013, Chapter 7) recommend that the same procedure be performed across
many different mutually exclusive and collectively exhaustive splits of the full date. This
procedure of building many models is called “K-fold cross-validation” (CV) and its purpose
is to integrate out the effect of a single training set to result in the unconditional estimate of
generalization.
In practice, how large should the training and test splits be? Depending on the size of the
test set relative to the training set, CV can trade bias for variance when estimating an out-
of-sample metric. Small training sets and large test sets give more biased estimates since the
training set is built with less data than the n observations given. However, large test sets have
lower variance estimates since they are composed of many examples. There is no consensus
in the literature about the optimal training-test split size (Hastie et al. 2013, page 242). 10-
fold CV is a common choice employed in many statistical applications and provides for a
relatively fast algorithm. In the limit, n models can be created by leavining each observation
out, as done in DeRubeis et al. (2014). In our software, we default to 10-fold cross validation
but allow for user customization. This estimation procedure outlined above is graphically
illustrated in the top of Figure 1.
For a Binary Response
In the binary case, the value is the expected probability of the positive outcome. However,
assessing improvement is slighly more complicated as there are generally three metrics to
compare differential response, (a) the probablity difference, (b) the risk ratio and (c) the odds
ratio. Thus, there are three ways of defining improvement, µI0 , . . .
(a) V [d]− V [d0], (b) V [d]
V [d0]
and (c)
V [d]
1−V [d]
V [d0]
1−V [d0] .
(10)
and the estimate of all three is found by placing hats above on all V ’s, d’s and d0’s.
Following the example in the previous section we employ the analagous model, a logistic linear
model with first order treatment interactions where the model f now denotes the probability
of the positive outcome y = 1,
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Figure 1: A graphical illustration of (1) our proposed method for estimation and (2) our pro-
posed method for inference on the population mean improvement of an allocation procedure
and (3) our proposed future allocation procedure. To compute the best estimate of the im-
provement Iˆ0, the RCT data goes through the K-fold cross validation procedure of Section 3.4
(depicted in the top center). The black slices of the data frame represent the test data. To
draw inference, we employ the non-parametric bootstrap procedure of Section 3.5 by sam-
pling the RCT data with replacement and repeating the K-fold CV to produce Iˆ10 , Iˆ
2
0 , . . . , Iˆ
B
0
(bottom). The grey slices of the data frame represent the duplicate rows in the original data
due to sampling with replacement. The confidence interval and significance of H0 : µI0 ≤ 0 is
computed from the bootstrap distribution (middle center). Finally, the practitioner receives
fˆ which is built with the complete RCT data (top left).
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f(xi1, Ai) = logit
(
β0 + β1x1 + . . .+ βpxp +Ai
(
γ0 + γ1′x1′ + . . .+ γp′xp′
))
.
This model, fit via maximum likelihood numerically (Agresti 2013), is the default in our
software implementation. Here, higher probabilities of success imply higher logit values so that
we have the same form of the decision rule estimate, dˆ[fˆx] = 1 when γˆ0+γˆ1′x1′+. . .+γˆp′xp′ > 0
If the risk ratio or odds ratio improvement metrics are desired, Equations 7 and 8 are modified
accordingly but otherwise estimation is then carried out the same as in the previous section.
For a Survival Response
Survival responses differ in two substantive ways from continuous responses: (1) they are
positive (2) some are “censored” which means it assumes the value of the last known mea-
surement but it is certain that the true value is greater. The responses y are coupled with
c, a binary vector of length n where the convention is to let ci = 1 to indicate that yi is a
non-censored value and ci = 0 to indicate that yi is censored and thus set equal to its last
known value.
To obtain dˆ, we require a survival model. For example purposes here we will assume the ex-
ponential regression model (the exponentiation enforces the positivity of the response values)
with the usual first order treatment interactions,
f(xi1, Ai) = exp
(
β0 + β1x1 + . . .+ βpxp +Ai
(
γ0 + γ1′x1′ + . . .+ γp′xp′
))
.
Under the exponential model, the convention is that the noise term E is multiplicative instead
of additive (i.e. Yi = f(xi1, Ai)Ei). Moreso than for continuous and incidence endpoints,
parameter estimation is dependent on the choice of error distribution. Following Hosmer and
Lemeshow (1999, Chapter 1), a flexible model is to let ln (E1) , . . . , ln (En) iid∼ Gumbel(0, σ2),
implying the popular Weibull model for survival time (although the user is free to choose
whatever model they wish). Parameters are fit using maximum likelihood taking care to
ensure the correct contributions of censored and uncensored values. Similar to the case of
logistic regression, the likelihood function does not have a closed form solution and must be
approximated numerically.
Some algebra demonstrates that the estimated decision rule under the linear Weibull echoes
those above, i.e. dˆ[fˆx] = 1 when γˆ0 + γˆ1′x1′ + . . . + γˆp′xp′ > 0. In other words, the subject
is given the treatment that yields the longest expected survival. Note that at this step, a
fully parametric model is needed; the non-parametric Kaplan-Meier or the semi-parametric
Cox proportion hazard model are insufficient as we need a means of explicitly estimating
E [Y | X,A] for all values of X and both values of A.
Subjects are then sorted in cells like Table 2 but care is taken to keep the corresponding ci
values together with their paired yi values, following Yakovlev et al. (1994). At this point, we
need to specify analagous computations to Equations 7 and 8 that are sensitive to the fact
that many yi values are censored. (The sample averages y¯ obviously cannot be employed here
because it ignores this censoring).
Of course we can reemploy a new Weibull model and define improvement as we did earlier as
the difference in expectations (Equation 2). However, there are no more covariates needed at
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this step as all subjects have been sorted based on dˆ(x). Thus, there is no reason to require
a parametric model that may be arbitrarily wrong.
For our default implementation, we have chosen to employ the difference of the Kaplan-Meier
median survival statistics here because we intuitively feel that a non-parametric estimate
makes the most sense. Once again, the user is free to employ whatever they feel is most
appropriate in their context. Given this default, please note that the improvement measure
of Equation 2 is no longer defined as the difference in survival expectations, but now the
difference in survival medians. This makes our framework slightly different in the case of
survival endpoints.
3.5. Inference for the population improvement parameter
The Iˆ0 estimates are elaborate estimates from a sample of data. We can employ the nonpara-
metric bootstrap to obtain an asymptotic estimate of its sampling variability, which can be
used to construct confidence intervals and testing procedures (Efron and Tibshirani 1994).
In the context of our proposed methodology, the bootstrap procedure works as follows for
the target of inference µIrandom . We take a sample with replacement from the RCT data of
size n denoted with tildes [X˜, y˜]. Using the 10-fold CV procedure described at the end of
Section 3.4, we create an estimate I˜random. We repeat the resampling of the RCT data and
the recomputation of I˜random B times where B is selected for resolution of the confidence
interval and significance level of the test. In practice we found B = 3000 to be sufficient, so
we leave this as the default in our software implementation. Because the n’s of usual RCT’s
are small, and the software is parallelized, this is not an undue computational burden.
In this application, the bootstrap approximates the sampling of many RCT datasets. Each
I˜ that is computed corresponds to one out-of-sample improvement estimate for a particular
RCT dataset drawn from the population of RCT datasets. The frequentist confidence intervals
and tests that we develop for the improvement measure do not constitute inference for a new
individual’s improvement, it is inference for the average improvement for future subjects.
To create an 1−α level confidence interval, first sort the {I˜Random,1, . . . , I˜Random,B} by value,
and then report the values corresponding to the empirical α/2 and 1− α/2 percentiles. This
is called the “percentile method.” There are other ways to generate asymptotically valid
confidence intervals using bootstrap samples but some debate about which has the best finite
sample properties. We have also implemented the the bias-corrected “BCa method” (Efron
1987) that DiCiccio and Efron (1996) claim performs an order of magnitude better in accuracy.
But in this paper’s examples we illustrate only the percentile method. Implementing other
confidence interval methods for the bootstrap may be useful future work.
If a higher response is better for the subject, we set H0 : µI0 ≤ 0 and Ha : µI0 > 0. Thus, we
wish to reject the null that our allocation procedure is at most as useful as a naive business-as-
usual procedure. To obtain an asymptotic p value, we count the number of bootstrap sample
I˜ estimates below 0 and divide by B. This bootstrap procedure is graphically illustrated in
the bottom half of Figure 1 and the bootstrap confidence interval and p value computation is
illustrated in the center. Note that for incidence outcomes where the improvement is defined
as the risk ratio or odds ratio, we use H0 : µI0 ≤ 1 and Ha : µI0 > 1 and count the number
of I˜ estimates below 1.
We would like to stress once again that we are not testing for qualitative interactions — the
ability of a covariate to “flip” the optimal treatment for subjects. Tests for such interactions
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would be hypothesis tests on the γ parameters and models of that form are not even required
for our procedure. Qualitative interactions are controversial and entire tests have been devel-
oped to investigate their significance (see beginning of Section 2) which most RCT’s are not
even powered to investigate. “Even if an optimal personalized medicine rule [based on such
interactions] can provide substantial gains it may be difficult to estimate this rule with few
subjects” (Rubin and van der Laan 2012). The bootstrap test (and our approach at large)
looks at the holistic picture of the model without focus on individual covariate-treatment
interaction effects to determine if the model in totality is useful, conceptually akin to the
omnibus F-test in OLS.
Concerns with using the bootstrap for inference in the value parameter
There is some concern in the personalized medicine literature about the use of the bootstrap.
First, the estimator for the value is a non-smooth functional of the data which may result
in an inconsistent bootstrap estimator (Shao 1994). The non-smoothness is due to the in-
dicator function in Equation 9 being non-differentiable (similar to the example in Horowitz
2001, Section 4.3.1). However, “the value of a fixed [response model] (i.e., one that is not
data-driven) does not suffer from these issues and has been addressed by numerous authors”
(Chakraborty and Murphy 2014). Since our value estimate is constructed out-of-sample, it
is merely a difference of sample averages of the hold-out response values that are considered
pre-sorted according to a fixed rule.2
There is an additional concern. Some bootstrap samples produce null sets for the “lucky
subjects” (i.e. P ∪ S = ∅ of Table 2 or equivalently, all values of the indicator in Equation 9
are zero). These are safe to ignore as we are only interested in the distribution of estimates
conditional on feasibility of estimation. Empirically, we have noticed as long as n > 20, there
are less than 1% of bootstrap samples that exhibit this behavior. Either way, we print out this
percentage when using the PTE package; large percentages warn the user that the inference
is suspect.
3.6. Future Subjects
The implementation of this procedure for future individuals is straightforward. Using the
RCT data, estimate f to arrive at fˆ . When a new individual, whose covariates denoted x∗,
enters a clinic, our estimated decision rule is calculated by predicting the response under both
treatments, then allocating the treatment which corresponds to the better outcome, dˆ(x∗).
This final step is graphically illustrated in the top left of Figure 1.
It is important to note that dˆ(x∗) is built with RCT data where treatment was allocated
randomly and without regard to the subject covariates. In the example of the first order
linear model with treatment interactions, the γ parameters have a causal interpretation —
conditional causation based on the values of the moderating covariates. Thus dˆ(x∗) reflects a
treatment allocation that causes the response to be higher (or lower). We reiterate that this
would not be possible with observational data which would suffer from elaborate confounding
relationships between the treatment and subject covariates (see discussion in Sections 2 and
2Note also that we do not have the additional non-smoothness created by Q-learning during the maximiation
step (see Chakraborty et al. 2010, Section 2.4) Regardless, as long as the functional can be well-approximated
by a linear statistic, the value estimator is asymptotically normal and the non-smoothness does not cause an
issue with inference.
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6.1).
4. Data Examples
4.1. Simulation with correct regression model
Consider RCT data with one covariate x where the true response function is known:
Y = β0 + β1X +A(γ0 + γ1X) + E (11)
where E is mean-centered. We employ f(x,A) as the true response function, E [Y | X,A].
Thus, d = d∗, the “optimal” rule in the sense that a practitioner can make optimal allocation
decisions (modulo noise) using d(x) = 1γ0+γ1x>0. Consider d0 to be the random allocation
procedure (see Table 1). Note that within the improvement score definition (Equation 2), the
notation EdX [Y ] is an expectation over the noise E and the joint distribution of X, A. After
taking the expectation over noise, the improvement under the model of Equation 11 becomes
µI0 = EX [β0 + β1X + 1γ0+γ1X>0(γ0 + γ1X)]− EX [β0 + β1X + 0.5(γ0 + γ1X)]
= EX [(1γ0+γ1x>0 − 0.5) (γ0 + γ1X)]
= γ0 (P (γ0 + γ1X > 0)− 0.5) + γ1 (EX [X1γ0+γ1x>0]− 0.5EX [X]) .
We further assume X ∼ N (µX , σ2X) and we arrive at
µI0 = (γ0 + γ1µX)
(
.5− Φ
(
−γ0
γ1
))
+ γ1
σX√
2pi
exp
(
− 1
2σ2X
(
−γ0
γ1
− µ
)2)
.
We simulate under a simple scenario to clearly highlight features of our methodology. If
µX = 0, σ
2
X = 1 and γ0 = 0, neither treatment T1 or T2 is on average better. However, if
x > 0, then treatment T2 is better in expectation by γ1 × x and analogously if x < 0, T1
is better by −γ1 × x. We then set γ1 =
√
2pi to arrive at the round number µI0 = 1. We
set β0 = 1 and β1 = −1 and let Ei iid∼ N (0, 1). We let the treatment allocation vector A
be a random block permutation of size n, balanced between T1 and T2. Since there is no
PATE, the random and best d0 procedures (Table 1) are the same in value. We then vary
n ∈ {100, 200, 500, 1000} to assess convergence for both d0 procedures and display the results
in Figure 2.
Convergence to µI0 = 1 is observed clearly for both procedures but convergence for d0 best
is slower than d0 rand. This is due to the Vˆ being computed with fewer samples: y¯test,
which uses all of the available data, versus y¯P∪Q or y¯R∪S , which uses only half the available
data on average (see Equations 7 and 8) Also note that upon visual inspection, our bootstrap
distributions seem to be normal. Non-normality in this distribution when using the software
package warns the user that the inference is suspect.
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Figure 2: Histograms of the bootstrap samples of the out-of-sample improvement measures for
d0 random (left column) and d0 best (right column) for the response model of Equation 11
for different values of n. Iˆ0 is illustrated with a thick black line. The CIµI0 ,95% computed by
the percentile method is illustrated by thin black lines.
In this section we assumed knowledge of f and thereby had access to an optimal rule. In the
next section we explore convergence when we do not know f but pick an approximate model
yielding a non-optimal rule.
4.2. Simulation with approximate regression model
Consider RCT data with a continuous endpoint where the true response model is
Y = β0 + β1X + β2U +A(γ0 + γ1X
3 + γ2U) + E (12)
where X denotes a covariate recorded in the RCT and U denotes a covariate that is not
included in the RCT dataset. The optimal allocation rule d∗ is 1 when γ0 + γ1X3 + γ2U > 0
and 0 otherwise. The practitioner, however, does not have access to the information contained
in U , the unobserved covariate, and has no way to ascertain the exact relationship between
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X and the treatment. Consider a reasonable model that is some approximation of the true
population response surface,
f(X,A) = β0 + β1X +A(γ0 + γ1X), (13)
which is different from the true response model due to (a) the misspecification of X (linear
instead of cubic) and (b) the absence of covariate U (see Equation 4). This is the more
realistic scenario; even with infinite data, the optimal treatment allocation procedure cannot
be found because of both an unknown model for the covariate known and a missing covariate.
To simulate, we set the X’s, U ’s and E ’s to be standard normal variables and then set β0 =
1, β1 = −1, β2 = 0.5, γ0 = 0, γ1 = 1 and γ2 = −3. The Xi’s and the Ui’s are deliberately
made independent of one another so that the observed covariates cannot compensate for the
unobserved covariates. The independence makes any comparison between the improvement
under d∗ and d more stark. To find the improvement when the true model’s d∗ is used to
allocate, we simulate under Equation 12 and obtain µ∗I0 ≈ 1.65 and analogously, to find the
improvement under approximation model’s d, we simulate under Equation 13 and obtain
µI0 ≈ 0.79. Further simulation shows that not observing U is responsible for 85% of this
observed drop in performance and employing the linear X in place of the non-linear X3 is
responsible for the remaining 15%. Since γ0 = 0, there is no PATE and thus these simulated
improvements apply to both the cases where d0 is random and d0 is best (Table 1).
Figure 3 demonstrates results for n = {100, 200, 500, 1000} analogous to Figure 2. We observe
that the bootstrap confidence intervals contain µI0 but not µ
∗
I0
. This is expected; we are not
allocating using an estimate of d∗, only an estimate of d.
Convergence towards µI0 ≈ 0.79 is observed clearly for both procedures and once again the
convergence is slower for the best procedure for the same reasons outlined in Section 4.1.
Note that the coverage illustrated here is far from µ∗I0 , the improvement using the optimal
allocation rule. Parenthetically, Kallus (2017) presents a coefficient of personalization metric
similar to R2 where a value of 100% represents perfect personalization and 0% represents
standard of care. Here, we would fall far short of the 100%.
The point of this section is to illustrate the realistic scenario that if the response model is
unknown and/or covariates are unobserved, the improvement of an allocation procedure may
fall short of optimal. However, the effort can still yield an improvement that can be clinically
significant and useful in practice.
In the next section, we explore using our procedure for RCT data from a real clinical trial
and thus the response model is latent meaning that µ∗I0 is inaccessible. The strategy is to
approximate the response function using a reasonable model f built from domain knowledge
and the variables at hand and hope to find demonstrate a positive, clinically meaningful µI0 .
4.3. Clinical trial demonstration
We consider the RCT data of DeRubeis et al. (2005) where there are two depression treat-
ments: cognitive behavioral therapy (T1) and an antidepressant medication paroxetine (T2)
on n = 154 subjects. The primary outcome measure y is the continuous Hamilton Rating
Scale for Depression (HRSD), a composite score of depression symptoms where lower means
less depressed, assessed by a clinician after 16 weeks of treatment. A simple t test revealed
that there was no statistically significant difference between the cognitive behavioral therapy
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Figure 3: Histograms of the bootstrap samples of the out-of-sample improvement measures for
d0 random (left column) and d0 best (right column) for the response model of Equation 12
for different values of n. Iˆ0 is illustrated with a thick black line. The CIµI0 ,95% computed via
the percentile method is illustrated by thin black lines. The true population improvement µ∗I0
given the optimal rule d∗ is illustrated with a dotted black line
and paroxetine. Despite the seeming lack of a PATE, practitioner intuition suggests that the
covariates collected can be used to build a principled personalized model with a significant
negative µI0 . The lack of an PATE also suggests that the random d0 is an appropriate
baseline comparison.
Of the measured patient characteristics, clinical experience and theory should suggest both
main effects and treatment moderating variables (see Cohen and DeRubeis 2017 for a discus-
sion on variable selection). For the purposes of this demonstration, we follow the variables
found in DeRubeis et al. (2014, Table 3). The main effects selected were baseline HRSD
score, IQ, age and presence of chronic depression; the treatment moderating variables were
marital status, employment status, degree of life stressors, personality disorder and whether
the patient was taking other drugs.3
When fitting a linear model to capture this theory, standard practice is to include the mod-
3Note that the variables selected in their work relied on previously published papers that analyzed the RCT
data and this is a form of data snooping. Such a strategy should be avoided as it may invalidate the inference
provided by our method. By what degree exactly — it is difficult to know.
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erators (the interaction effects) also as mediators (the main effects). Note that this is not
absolutely essential here, where our goal is neither inference for the contributions of the vari-
ables nor prediction of the dependent variable. The next Section will demonstrate how a
model such as this one is entered into our software and fit with least squares to generate dˆ.
The improvement estimates, their confidence intervals and their statistical significances are
outputted below and they are also illustrated graphically via histograms of the bootstrap
samples in Figure 4.
I_random observed_est = -0.842, p val = 0.001,
95% CI's: pctile = [-2.657, -0.441]
I_best observed_est = -0.765, p val = 0.039,
95% CI's: pctile = [-2.362, 0.134]
−4 −3 −2 −1 0 1
(a) I˜Rand bootstrap samples
−4 −3 −2 −1 0 1
(b) I˜Best bootstrap samples
Figure 4: Histograms of the bootstrap samples (B = 3, 000) of improvement measures for the
personalization model described in the text for the RCT data of DeRubeis et al. (2014). Both
random and best d0 business-as-usual allocation procedures are displayed. The thick black
line is the best estimate of Iˆ0, the thin black lines are the confidence interval computed via
the percentile method.
From these results, we anticipate that a new subject allocated using the model f will be less
depressed on average by 0.84 HRSD units compared to that same subject being allocated ran-
domly to cognitive behavioral therapy or paroxetine. We can easily reject the null hypothesis
that personalization is no better than random allocation for a new subject (p value = 0.004).
In short, the results are statistically significant, but the estimated improvement may not be
of great clinical importance. According to the criterion set out by the National Institute for
Health and Care Excellence, three points on the HRSD is considered clinically important.
However, the statistical significance suggests that nevertheless the model f fit using this data
set and its corresponing personalization rule dˆ(x) could be implemented in practice with new
patients for a modest improvement in patient outcome at little cost.
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5. The PTE Package
5.1. Estimation and Inference for Continuous Outcomes
The package comes with two example datasets. The first is the continuous data example.
Below we load the library and data.
R> library(PTE); library(dplyr)
R> data(continuous_example)
R> X = continuous_example$X
R> y = continuous_example$y
R> continuous_example$X %>% sample_n(5)
# A tibble: 5 x 6
treatment x1 x2 x3 x4 x5
<dbl> <fctr> <fctr> <fctr> <fctr> <dbl>
1 1 NO OFF YES MEDIUM 1.3009448
2 0 YES OFF YES MEDIUM -0.5483983
3 0 NO OFF YES LOW 0.3762733
4 1 NO OFF YES MEDIUM -1.1648459
5 1 YES ON YES HIGH -0.8566221
> round(head(continuous_example$y), 3)
[1] -0.746 -1.359 0.020 0.632 -0.823 -2.508
As we can see, the endpoint y is continuous and the RCT data has a binary treatment vector
appropriately named (this is required) and five covariates, four of which are factors and one
is continous.
We can run the estimation for the improvement score detailed in Section 3.4.1 and the infer-
ence of Section 3.5 by running the following code.
R> pte_results = PTE_bootstrap_inference(X, y, B = 1000, num_cores = 4)
where 1000 bootstrap samples were used and four cores were used in parallel to minimize
runtime. The model defaults to a linear model where all variables included are interacted
with the treatment and fit with least squares. Below are the results. The software also plots
the results as in Figure 4 (unshown for all of the examples in this section).
R> pte_results
I_random observed_est = 0.077, p val = 0.014,
95% CI's: pctile = [0.021, 0.41],
I_best observed_est = 0.065, p val = 0.078,
95% CI's: pctile = [-0.053, 0.336],
To demonstrate the flexibility of the software, consider the case where the user wishes to use
x1, x2, x3, x4 as mediators and x5 as the sole treatment moderator. And further, the user
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wishes to estimate the model parameters using the ridge penalty instead of OLS. Note that
this is an elaborate model that would be difficult to justify in practice and it is only introduced
here for illustration purposes. Below is the code used to test this approach to personalization.
R> library(glmnet)
R> pte_results = PTE_bootstrap_inference(X, y, B = 1000, num_cores = 4,
personalized_model_build_function = function(Xytrain){
Xytrain_mm = model.matrix(~ . - y + x5 * treatment, Xytrain)
cv.glmnet(Xytrain_mm, Xytrain[, ncol(Xytrain)], alpha = 0)
},
predict_function = function(mod, Xyleftout){
Xyleftout$censored = NULL
Xyleftout_mm = model.matrix(~ . + x5 * treatment, Xyleftout)
predict(mod, Xyleftout_mm)
})
Here, the user passes in a custom function that builds the ridge model to the argument
personalized_model_build_function. The specification for ridge employed here uses the
package glmnet (Friedman et al. 2010) that picks the optimal ridge penalty hyperparameter
automatically. Unfortunately, there is added complexity: the glmnet package does not accept
formula objects and thus model matrices are generated both upon model construction and
during prediction. This is the reason why a custom function is also passed in via the argument
predict_function which wraps the default glmnet predict function by passing in the model
matrix.
5.2. Estimation and Inference for Binary Outcomes
In order to demonstrate our software for the incidence outcome, we use the previous data
but threshold its response arbitrarily at its 75%ile to create a mock binary response (for
illustration purposes only).
R> y = ifelse(y > quantile(y, 0.75), 1, 0)
We then fit a linear logistic model using all variables as fixed effects and interaction effects
with the treatment. As discussed in Section 3.4.2, there are three improvement metrics for
incidence outcomes. The default is the odds ratio. The following code fits the model and
performs the inference.
R> pte_results = PTE_bootstrap_inference(X, y,
regression_type = "incidence", B = 1000, num_cores = 4)
Warning message:
glm.fit: fitted probabilities numerically 0 or 1 occurred
Note that the response type incidence has to be explicitly made known otherwise the default
would be regression. Below are the results.
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R> pte_results
I_random observed_est = 1.155, p val = 0.103,
95% CI's: pctile = [0.848, 2.067],
I_best observed_est = 1.04, p val = 0.333,
95% CI's: pctile = [0.663, 1.759],
The p value is automatically calculated for H0 : µI0 < 1 (i.e. the odds of improvement is
better in d0 than d). Other tests can be specified by changing the H_0_mu_equals argument.
Here, the test failed to reject H0. Information is lost when a continuous metric is coerced to
be binary. If the user wished to define improvement via the risk ratio (or straight probability
difference), an argument would be added to the above, incidence_metric = "risk_ratio"
(or "probability_difference").
5.3. Estimation and Inference for Survival Outcomes
Our package also comes with a mock RCT dataset with a survival outcome. Below, we load
the data.
R> data(survival_example)
R> X = survival_example$X
R> y = survival_example$y
R> censored = survival_example$censored
There are four covariates, one factor and three continuous. We can run the estimation for
the improvement score detailed in Section 3.4.3 and inference for the true improvement by
running the following code.
R> pte_results = PTE_bootstrap_inference(X, y, censored = censored,
regression_type = "survival", B = 1000, num_cores = 4)
The syntax is the same as the above two examples except here we pass in the binary c vector
separately and declare that the endpoint type is survival. Again by default all covariates are
included as main effects and interactions with the treatment in a linear Weibull model.
In the default implementation for the survival outcome, improvement is defined as median
survival difference of personalization versus standard of care. The median difference can be
changed via the user passing in a new function with the difference_function argument.
The median difference results are below.
R> pte_results
I_random observed_est = 0.148, p val = 0.027,
95% CI's: pctile = [-0.003, 0.28],
I_best observed_est = -0.041, p val = 0.679,
95% CI's: pctile = [-0.164, 0.038],
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It seems that the personalized medicine model increases median survival by 0.148 versus d0
being the random allocation of the two treatments. If survival was measured in years (the
typical unit), this would be about 2 months. However, it cannot beat the d0 being the best of
the two treatments. Remember, this is a much more difficult improvement metric to estimate
as we are really comparing two cells in Table 2 to another two cells, one of which is shared.
Thus the sample size is low and power suffers. This is particularly difficult in the survival
case when censored observations add little information thus adding insult to injury.
6. Discussion
We have provided a methodology to test the effectiveness of personalized medicine models.
Our approach combines RCT data with a statistical model f of the response for estimating
improved outcomes under different treatment allocation protocols. Using the non-parametric
bootstrap and cross-validation, we are able to provide confidence bounds for the improvement
and hypothesis tests for whether d[f ] performs better compared to a business-as-usual pro-
cedure. We demonstrate the method’s performance on simulated data and on data from a
clinical trial on depression. We also present our statistical methods in an open source software
package in R named PTE which is available on CRAN.
6.1. Future Directions
Our method and corresponding software have been developed for a particular kind of RCT
design. The RCT must have two arms and one endpoint (continuous, incidence or survival).
An extension to more than two treatment arms is trivial as Equation 3 is already defined
generally. Implementing extensions to longitudinal or panel data as well as count outcomes
are worthy next steps within our scope here.
We concur that “a ‘once and for all’ treatment strategy [may be] suboptimal due to its
inflexibility”(Zhao et al. 2015), but this one-stage treatment situation is all too common in the
literature and the data is available to work with. We consider an extended implementation for
dynamic treatment regimes on multi-stage experiments fruitful future work. Consider being
provided with RCT data from sequential multiple assignment randomized trials (SMARTs,
Murphy 2005b) and an a priori response model f . The estimate of Vˆ (dˆ) (Equation 6) can be
updated for a SMART with k stages (Chakraborty and Murphy 2014) where our Table 2 is a
summary for only a single stage. In a SMART with k stages, the matrix becomes a hypercube
of dimension k. Thus, the average of diagonal entries in the multi-dimensional matrix is the
generalization of the estimate of Vˆ (dˆ) found in Equation 7. Many of the models for dynamic
treatment regimes found in Chakraborty and Moodie (2013) can then be incorporated into our
methodology as d, and we may be able to provide many of these models with valid statistical
inference. Other statistics computed from this multi-dimensional matrix may be generalized
as well.
Our choices of d0 explored herein were limited to the random or the best rules (see Table 1).
There may be other business-as-usual allocation procedures to use here that make for more
realistic baseline comparisons. For instance, one can modify best to only use the better
treatment if a two-sample t-test rejects at prespecified Type I error level and otherwise default
to random. One can further set d0 to be a regression model or a physician’s decision tree
model and then use our framework to pit two models against each other.
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It might also be useful to consider building from an observational design rather than a ran-
domized controlled trial. The literature reviewed in Section 2 generally does not require RCT
data but “only” a model that accurately captures selection into treatments e.g. if “the [elec-
tronic medical record] contained all the patient information used by a doctor to prescribe
treatment up to the vagaries and idiosyncrasies of individual doctors or hospitals” (Kallus
2017, Section 1). This may be a very demanding requirement in practice. In this paper, we
do not even require valid estimates of the true population response surface. In an observa-
tional study one would need that selection model to be correct and/or a correct model of the
way in which subjects and treatments were paired (see Freedman and Berk 2008). Although
assuming one has a model that captures selection, it would be fairly straightforward to up-
date the estimators of Section 3.4 to inverse weight by the probability of treatment condition
(the “IPWE”) making inference possible for observational data (e.g. see Zhang et al. 2012b;
Chakraborty and Murphy 2014; Kallus 2017).
However the most exigent further work is dropping the requirement of the model f a priori.
This is a tremendous constraint in practice: what if the practitioner cannot construct a
suitable f using domain knowledge and past research? It is tempting to use a machine
learning model that will both specify the structure of f and provide parameter estimates
within (e.g. the personalization forests of Kallus 2017). It is unknown if the bootstrap of
Section 3.5 will withstand such a machination and we are awaiting a rigorous proof. Is there
a solution in the interim?
As suggested as early as Cox (1975), we can always pre-split the data in two where the first
piece can be used to specify f and the second piece can be injected into our procedure. The
cost of course is less data for estimation and thus, less power available to prove that the
personalization is effective.
If we do not split, all the data is to be used and there are three scenarios that pose different
technical problems. Under one scenario, a researcher is able to specify a suite of possible
models before looking at the data. The full suite can be viewed as comprising a single pro-
cedure for which nonparametric bootstrap procedures may in principle provide simultaneous
confidence intervals (Buja and Rolke 2014). Under the other two scenarios, models are devel-
oped inductively from the data. This problem is more acute when we begin to incorporate
genomic data for personalization (Davies 2015). Here, there will be many more features (pos-
sibly millions of single-nucleotide polymorphisms) than samples and model selection must be
employed. If it is possible to specify exactly how the model search us undertaken (e.g., using
the lasso), some forms of statistical inference may be feasible. This is currently an active
research area; for instance, Lockhart et al. (2013); Lee et al. (2016) develop a significance test
for the lasso and there is even some evidence to suggest that the double-peeking is not as
problematic as the community has assumed (Zhao et al. 2017).
Replication
The results and simulations in this paper (for which the code was not expressly found
herein) can be duplicated by running the R scripts found at github.com/kapelner/PTE/
tree/master/paper_duplication. Note that we cannot release the depression data of Sec-
tion 4.3 due to privacy concerns.
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